TY - JOUR
T1 - Flavivirus NS4B protein
T2 - Structure, function, and antiviral discovery
AU - Wang, Yan
AU - Xie, Xuping
AU - Shi, Pei Yong
N1 - Funding Information:
We thank colleagues at the University of Texas Medical Branch and the Novartis Institute for Tropical Diseases for helpful discussions. P.-Y.S. was supported by NIH grants U19AI171413 , U19AI142759 , and U01AI151801 , and awards from the Sealy & Smith Foundation, the Kleberg Foundation , the John S. Dunn Foundation, the Amon G. Carter Foundation, the Summerfield Robert Foundation, and the Edith and Robert Zinn Foundation .
Funding Information:
We thank colleagues at the University of Texas Medical Branch and the Novartis Institute for Tropical Diseases for helpful discussions. P.-Y.S. was supported by NIH grants U19AI171413, U19AI142759, and U01AI151801, and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Summerfield Robert Foundation, and the Edith and Robert Zinn Foundation.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/11
Y1 - 2022/11
N2 - Infections with mosquito-borne flaviviruses, such as Dengue virus, ZIKV virus, and West Nile virus, pose significant threats to public health. Flaviviruses cause up to 400 million infections each year, leading to many forms of diseases, including fatal hemorrhage, encephalitis, congenital abnormalities, and deaths. Currently, there are no clinically approved antiviral drugs for the treatment of flavivirus infections. The non-structural protein NS4B is an emerging target for drug discovery due to its multiple roles in the flaviviral life cycle. In this review, we summarize the latest knowledge on the structure and function of flavivirus NS4B, as well as the progress on antiviral compounds that target NS4B.
AB - Infections with mosquito-borne flaviviruses, such as Dengue virus, ZIKV virus, and West Nile virus, pose significant threats to public health. Flaviviruses cause up to 400 million infections each year, leading to many forms of diseases, including fatal hemorrhage, encephalitis, congenital abnormalities, and deaths. Currently, there are no clinically approved antiviral drugs for the treatment of flavivirus infections. The non-structural protein NS4B is an emerging target for drug discovery due to its multiple roles in the flaviviral life cycle. In this review, we summarize the latest knowledge on the structure and function of flavivirus NS4B, as well as the progress on antiviral compounds that target NS4B.
KW - Antivirals
KW - Drug discovery
KW - Flavivirus
KW - Nonstructural protein 4B
UR - http://www.scopus.com/inward/record.url?scp=85139318539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139318539&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2022.105423
DO - 10.1016/j.antiviral.2022.105423
M3 - Review article
C2 - 36179934
AN - SCOPUS:85139318539
SN - 0166-3542
VL - 207
JO - Antiviral research
JF - Antiviral research
M1 - 105423
ER -